Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Leukemia, Myeloid, Acute 3Leukemia, Lymphocytic, Chronic, B-Cell 3Multiple Myeloma 2Lymphoma, Non-Hodgkin 2Waldenstrom Macroglobulinemia 1Neuroblastoma 1Leukemia, Prolymphocytic, T-Cell 1Hematologic Neoplasms 1Breast Neoplasms 1Amyloidosis 1

Interventions

miridesap 3Dexamethasone 3Cyclophosphamide 2Bortezomib 2venetoclax 1ixazomib 1daratumumab 1birtamimab 1belantamab mafodotin 1Pharmaceutical Preparations 1Lisaftoclax 1GTP Cyclohydrolase 1Drug Evaluation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Amyloidosis × Lisaftoclax × Clear all
NCT04942067 2023-10-25

APG-2575 in Combination With Novel Therapeutic Regimens in Subjects With Relapsed or Refractory Multiple Myeloma

Ascentage Pharma Group Inc.

Phase 1/2 Unknown
108 enrolled
Plasma cell

Amyloidosis, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡